Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

October 3, 2013

Primary Completion Date

May 31, 2015

Study Completion Date

May 31, 2015

Conditions
Respiratory Syncytial Virus Infections
Interventions
BIOLOGICAL

RSV cps2 Vaccine

10\^5.3 plaque forming units (PFUs) or RSV cps2 vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).

BIOLOGICAL

Placebo Vaccine

Placebo vaccine will be administered as nose drops (0.25 mL per nostril, for a total of 0.5 mL).

Trial Locations (5)

60612

Rush Univ. Cook County Hosp. Chicago NICHD CRS, Chicago

80045

The Children's Hospital University of Colorado, Denver

90806

Miller Children's Hospital at Long Beach Memorial Medical Center, Long Beach

92093-0672

University of California, UC San Diego CRS, La Jolla

60614-3393

Chicago Children's CRS, Chicago

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT01968083 - Evaluating the Safety and Immune Response to a Single Dose of a Respiratory Syncytial Virus (RSV) Vaccine in RSV-Seronegative Infants and Children | Biotech Hunter | Biotech Hunter